Posted by Michael Wonder on 22 May 2024
Atara Biotherapeutics submits tabalecleucel (tab-cel) biologics license application for treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease with US FDA
20 May 2024 - First allogeneic T-cell therapy BLA submission to US FDA.
Atara Biotherapeutics today announced that Atara has submitted a biologics license application to the US FDA for tabelecleucel (tab-cel) indicated as monotherapy for treatment of adult and paediatric patients two years of age and older with Epstein-Barr virus positive post-transplant lymphoproliferative disease who have received at least one prior therapy.
